

IN THE CLAIMS

Please rewrite claims 44-48, 65, 66, 69 and 121 as follows:

44. A method for providing an artificial chemotactic factor gradient *in vivo* comprising administering a composition comprising one or more chemotactic factor(s).

45. The method of claim 44 wherein the composition further comprises a device.

46. The method of claim 44 wherein the chemotactic factor is a chemokine.

47. The method of claim 46 wherein the composition further comprises a device.

48. The method of claim 45 wherein the device is ethylene-vinyl-acetate.

65. The method of claim 44, 45 or 133 wherein the chemotactic factor is selected from the group consisting of chemokines, nucleotides and neuropeptides.

66. The method of claim 46, 47, 48 or 133 wherein the chemokine is selected from the group consisting of MIP-1 γ , RANTES, MCP-3, MIP-5, MCPs, TARC, MDC, MIP-3 γ , IL-8, SDF-1, MIP-3 γ and SLC.

69. The method of claim 66 wherein the chemokine is MIP-3 γ .

121. The method of claim 44 and 45 wherein the composition is administered subcutaneously.

Please add the following new claim:

133. The method of claim 47 wherein the device is ethylene-vinyl-acetate.

Please **cancel** claims 1-43, 49-64, 70-120 and 122-132 without prejudice.

REMARKS

This paper is being filed in response to the Office Communication dated September 19, 2002. Applicants respectfully request reconsideration of the above-identified application in light of the amendments and remarks presented herein.

Claims 1-132 are pending. Claims 1-43, 49-64, 70-120 and 122-132 have been cancelled. Claims 44-48, 65, 66, 69 and 121 have been amended to better indicate the relationship of these claims to their respective independent claims. New claim 133 has been added. No new matter has been introduced by the amendments to the claims or the addition of claim 133.